The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.¹

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)¹

Nothing less than the opportunity
to reach for their treatment goals

For your patients, that’s everything.

ROBUST JOINT EFFICACY

SKYRIZI met its primary endpoint (ACR20 at Week 24) in 2 clinical trials.¹

ACR20/50/70, complete resolution of enthesitis/dactylitis, and minimal disease activity at Week 24 with results up to ~1 year in PsA.^1-3 *

VIEW JOINT EFFICACY

DURABLE SKIN CLEARANCE

PASI 90 response vs placebo at Week 24 with response rates at 1 year in PsA.^2,3 *

VIEW SKIN CLEARANCE

WELL-STUDIED SAFETY PROFILE

Evaluated in 19 clinical trials (2 PsA, 17 Ps). The safety profile in PsA is generally consistent with the safety profile of Ps.^1,4

VIEW SAFETY

Exceptional Access & Support

>95% preferred^† commercial and Medicare Part D coverage for PsA^5‡

VIEW ACCESS AND SUPPORT

*In an OLE, there is a potential for enrichment of the long-term data in remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.

^†Preferred means SKYRIZI is placed on the plan's preferred formulary.

ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR50=improvement of at least 50% in tender joint count, swollen joint count, and at least 3 other core criteria; ACR70=improvement of at least 70% in tender joint count, swollen joint count, and at least 3 other core criteria. PASI 90=≥90% improvement in Psoriasis Area and Severity Index.

PREFERRED^† COMMERCIAL AND
MEDICARE PART D COVERAGE FOR
PsA^5‡

VIEW COVERAGE AND ACCESS

National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of July 2022.

^‡Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

MAY HELP ELIGIBLE PATIENTS ACCESS
SKYRIZI AT NO CHARGE^§

Download or email Skyrizi Complete Enrollment and Prescription Form

DOWNLOAD

^§Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

Peer-Led Discussions about skyrizi FOR patients with PsA

EFFICACY & SAFETY RESULTS WITH SKYRIZI

Dr. Schwartzman and Dr. Khattri review the clinical efficacy endpoints from the PsA trials, including ACR20/50/70, ACR components such as patient-reported pain, and enthesitis and dactylitis, then conclude with a discussion of SKYRIZI's safety profile across 2 indications.

VIEW JOINT EFFICACY

SKYRIZI IN BIO-NAÏVE PATIENTS

Dr. Schwartzman and Dr. Khattri define how a bio-naïve patient may present in clinical practice and review the demographics of the patient population evaluated in the KEEPsAKE 1 PsA trial.

VIEW PATIENT IDENTIFICATION

SKYRIZI® is the #1 prescribed biological treatment for plaque psoriasis patients.

^‖As of 10/2021. New patients defined as bio-naïve; switch patients defined as bio-experienced switching biologics. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP) through proprietary method on diagnosis classification.

ACR20 Achieved At Week 24 with Response Rates Sustained At 1 year^1-3,7,8

KEEPsAKE 1:

57% of patients achieved ACR20 at Week 24 vs 34% for placebo (primary endpoint)^¶

70% observed ACR20 at Week 52 in OLE (after 5 doses)

KEEPsAKE 2:

51% of patients achieved ACR20 at Week 24 vs 27% for placebo (primary endpoint)^¶

59% observed ACR20 at Week 52 in OLE (after 5 doses)

^¶Multiplicity-controlled P≤0.001 SKYRIZI vs placebo comparison.

VIEW JOINT EFFICACY

OLE LIMITATIONS:

In an OLE, there is a potential for enrichment of the long-term data in remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.

STUDY DESIGN:

KEEPsAKE 1 (N=964) and KEEPsAKE 2 (N=443) were 2 randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI 150 mg vs placebo over 24 weeks with a long-term, open-label extension for up to an additional 204 weeks. Both studies enrolled adult patients with active psoriatic arthritis. In KEEPsAKE 1, the study population had an inadequate response or intolerance to at least 1 csDMARD while in KEEPsAKE 2 patients had an inadequate response or intolerance to at least 1 biologic therapy OR to at least 1 csDMARD.^1-3